These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38185772)

  • 21. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
    Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB; Ibler KS
    J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
    Leutz A; Pinter A; Thaçi D; Augustin M; Schuster C; Fotiou K; Hundemer HP; Saure D; Mrowietz U; Reich K
    Br J Dermatol; 2021 Mar; 184(3):548-550. PubMed ID: 32940343
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.
    Gümüşel M; Özdemir M; Mevlitoğlu I; Bodur S
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1080-4. PubMed ID: 21118309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis.
    He F; Long FY; Zhang ZQ; Xia RY; Lu Y; Yin ZQ
    Clin Exp Dermatol; 2022 Feb; 47(2):432-433. PubMed ID: 34510518
    [No Abstract]   [Full Text] [Related]  

  • 28. Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience.
    Brunasso A
    J Drugs Dermatol; 2022 Aug; 21(8):914-916. PubMed ID: 35946963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis.
    Starace M; Alessandrini A; Iorizzo M; D'Altobrando A; Ferrari T; Bruni F; Piraccini BM
    Clin Exp Dermatol; 2022 Jun; 47(6):1165-1168. PubMed ID: 35118697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
    Ozmen I; Erbil AH; Koc E; Tunca M
    J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
    [No Abstract]   [Full Text] [Related]  

  • 31. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
    Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
    J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
    Patsatsi A; Kyriakou A; Sotiriadis D
    J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
    Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
    Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
    Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.
    Egeberg A; Wu JJ; Korman N; Solomon JA; Goldblum O; Zhao F; Mallbris L
    J Am Acad Dermatol; 2018 Jul; 79(1):104-109.e8. PubMed ID: 29548945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case report: Intralesional secukinumab injection for pediatric nail psoriasis: does it have to be a positive outcome?
    Wang X; Sun Y; Xie W; Liu H; Liu G
    Front Immunol; 2024; 15():1435141. PubMed ID: 39439789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.
    Cather JC; Young CT; Young MS; Cather JC
    Expert Opin Biol Ther; 2021 Aug; 21(8):983-990. PubMed ID: 34106794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.